EBS
Price
$3.26
Change
-$0.17 (-4.96%)
Updated
Sep 22, 6:59 PM EST
39 days until earnings call
SUPN
Price
$28.17
Change
+$0.54 (+1.95%)
Updated
Sep 22, 6:59 PM EST
44 days until earnings call

Analysis and predictions EBS vs SUPN

Header iconEBS vs SUPN Comparison
Open Charts EBS vs SUPNBanner chart's image
Emergent Biosolutions
Price$3.26
Change-$0.17 (-4.96%)
Volume$620.17K
CapitalizationN/A
Supernus Pharmaceuticals
Price$28.17
Change+$0.54 (+1.95%)
Volume$188.38K
CapitalizationN/A
View a ticker or compare two or three
EBS vs SUPN Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
EBS vs. SUPN commentary
Sep 24, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and SUPN is a Hold.

COMPARISON
Comparison
Sep 24, 2023
Stock price -- (EBS: $3.26 vs. SUPN: $28.17)
Brand notoriety: EBS and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 55% vs. SUPN: 79%
Market capitalization -- EBS: $168.89M vs. SUPN: $1.54B
EBS [@Pharmaceuticals: Other] is valued at $168.89M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.54B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $81.33B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, both EBS and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 3 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 3 bullish, 4 bearish.
  • SUPN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both EBS and SUPN are a bad buy in the short-term.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а -17.88% price change this week, while SUPN (@Pharmaceuticals: Other) price change was -3.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.68%. For the same industry, the average monthly price growth was +17.37%, and the average quarterly price growth was +9.99%.

Reported Earning Dates

EBS is expected to report earnings on Nov 02, 2023.

SUPN is expected to report earnings on Nov 07, 2023.

Industries' Descriptions

@Pharmaceuticals: Other (+2.68% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for EBS with price predictions.
OPEN
A.I.dvisor published
a Summary for SUPN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SUPN($1.54B) has a higher market cap than EBS($169M). SUPN has higher P/E ratio than EBS: SUPN (37.04) vs EBS (17.73). SUPN YTD gains are higher at: -21.026 vs. EBS (-72.396). SUPN has higher annual earnings (EBITDA): 116M vs. EBS (-343.2M). SUPN has more cash in the bank: 152M vs. EBS (88.6M). SUPN has less debt than EBS: SUPN (42.2M) vs EBS (903M). EBS has higher revenues than SUPN: EBS (1.07B) vs SUPN (634M).
EBSSUPNEBS / SUPN
Capitalization169M1.54B11%
EBITDA-343.2M116M-296%
Gain YTD-72.396-21.026344%
P/E Ratio17.7337.0448%
Revenue1.07B634M169%
Total Cash88.6M152M58%
Total Debt903M42.2M2,140%
FUNDAMENTALS RATINGS
EBS vs SUPN: Fundamental Ratings
EBS
SUPN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9682
PRICE GROWTH RATING
1..100
9782
P/E GROWTH RATING
1..100
1542
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (67) in the Biotechnology industry is in the same range as SUPN (80) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's SMR Rating (82) in the Pharmaceuticals Other industry is in the same range as EBS (96) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.

SUPN's Price Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as EBS (97) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (15) in the Biotechnology industry is in the same range as SUPN (42) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSSUPN
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 24 days ago
73%
Bullish Trend 26 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 4 days ago
69%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
N/A
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COSAX9.560.03
+0.31%
Columbia Overseas Core A
FWWNX71.040.16
+0.23%
American Funds New World 529-F-3
ATGRX11.20-0.02
-0.18%
American Century International Gr R
HOOCX24.59-0.08
-0.32%
Hartford Schroders US Small Cap Opps C
HISFX12.34-0.08
-0.64%
Hennessy Small Cap Financial Instl

SUPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with ANIP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+1.95%
ANIP - SUPN
45%
Loosely correlated
-1.37%
EBS - SUPN
39%
Loosely correlated
-5.23%
COLL - SUPN
37%
Loosely correlated
-1.37%
EVO - SUPN
37%
Loosely correlated
+1.37%
IRWD - SUPN
36%
Loosely correlated
-1.28%
More